コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 compound, 42a (MTC420), displays acceptable antituberculosis activity (Mtb IC50 = 525 nM, Mtb Wayne
2 discovery of novel compounds with increased antituberculosis activity in vitro and a better understa
3 ester (compound 3) with previously reported antituberculosis activity is rapidly converted to two me
4 ed that one of the compounds, 15f, possessed antituberculosis activity, with an MIC value of 3.13 mic
13 ::Km(r) was more sensitive to the front-line antituberculosis agent isonicotinic acid hydrazide (INH)
14 ed the use of ethambutol (EMB), a first-line antituberculosis agent that is known to inhibit cell wal
18 24 h after the organisms were incubated with antituberculosis agents by using fluorescein diacetate (
19 have been identified as a promising class of antituberculosis agents from phenotypic screening agains
20 f this methodology for rapidly assessing new antituberculosis agents may be limited by the relatively
21 an ongoing effort to develop new and potent antituberculosis agents, a second-generation series of n
34 bactericidal activity of orally administered antituberculosis (anti-TB) drugs was determined in a who
35 ity of isoniazid during the initial phase of antituberculosis (anti-TB) therapy has been attributed n
36 ough its peroxidase cycle, of the front line antituberculosis antibiotic isoniazid (isonicotinic acid
37 the enzyme responsible for activation of the antituberculosis antibiotic isoniazid (isonicotinic acid
40 week has potent activity in mouse models of antituberculosis chemotherapy, but efficacy and safety d
45 CD4(+) or CD8(+) T effector cells producing antituberculosis cytokine IFN-gamma in the context of im
48 the DDTs used for evaluating the efficacy of antituberculosis drug combinations and the gaps in the e
49 -development tools (DDTs) have been used for antituberculosis drug development over several decades.
56 n this Review, we discuss recent advances in antituberculosis drug discovery and development, clinica
61 2-pyridylcarboxaldehyde with the first-line antituberculosis drug isoniazid [i.e., isonicotinic acid
62 s--including an InhA mutant resistant to the antituberculosis drug isoniazid and a strain overexpress
64 However, KatG also activates the front-line antituberculosis drug isoniazid, hence rendering M. tube
72 ed to work together to strengthen the global antituberculosis drug pipeline and support the developme
74 have to be treated with currently available antituberculosis drug regimens for more than 20 months,
77 notypic screen for mutations associated with antituberculosis drug resistance and for the G(1031)A po
79 stance using data from the Global Project on Antituberculosis Drug Resistance Surveillance at WHO, fr
80 wana in the 1990s have recorded low rates of antituberculosis drug resistance, despite a three-fold r
85 m of action of isoniazid (INH), a first-line antituberculosis drug, is complex, as mutations in at le
86 Human NAT2 acetylates and inactivates the antituberculosis drug, isoniazid (INH), and is polymorph
91 ells per kg), within 4 weeks of the start of antituberculosis-drug treatment in a specialist centre i
94 ther this may be due to interactions between antituberculosis drugs and antiretrovirals needs to be i
96 LM could provide targets for development of antituberculosis drugs and for derivation of attenuated
97 predict resistance to first- and second-line antituberculosis drugs and validated our predictions in
100 rch focused on drug development, several new antituberculosis drugs are in the pipeline, and the stan
104 ciated with increased rates of resistance to antituberculosis drugs in both the New York City area an
106 azinamide and fluoroquinolones are essential antituberculosis drugs in new rifampicin-sparing regimen
107 because resistance to bedaquiline and other antituberculosis drugs is caused by mutations within a s
108 g-drug interactions involving the first-line antituberculosis drugs is reviewed in this article, alon
109 eptibility testing (DST) for the second-line antituberculosis drugs is slow, leading to diagnostic de
111 Mycobacterium tuberculosis by the first-line antituberculosis drugs isoniazid (INH) and ethambutol (E
112 rculosis complex were patient treatment with antituberculosis drugs prior to testing and the presence
113 arison of the early bactericidal activity of antituberculosis drugs should be evaluated using the tim
114 ates were susceptible in vitro to all of the antituberculosis drugs tested, 11 were monoresistant to
115 has also been progress in development of new antituberculosis drugs that are active against dormant o
117 articipating laboratories for the first-line antituberculosis drugs used in the United States-isoniaz
119 s, those who started fewer than three active antituberculosis drugs were at a higher risk of tubercul
120 osure to isoniazid or ethambutol, front-line antituberculosis drugs which also target the cell envelo
121 on of efavirenz and weeks 22 (efavirenz plus antituberculosis drugs) and 50 (efavirenz alone) after i
122 t with rIFN-gamma aerosol in addition to the antituberculosis drugs, 10 of 10 patients had increased
123 rculosis health services, development of new antituberculosis drugs, adjunct therapies and vaccines,
124 rifampin (RIF) are two of the most important antituberculosis drugs, and resistance to both of these
125 disease, the metabolism and distribution of antituberculosis drugs, and the toxicity experienced.
126 s and found that tolerance developed to most antituberculosis drugs, including the newer agents moxif
127 started a regimen with at least three active antituberculosis drugs, those who started fewer than thr
129 stablished for the majority of commonly used antituberculosis drugs, with a convenient 7H9 broth micr
149 ions that a DDT should answer with regard to antituberculosis drugs: What combination(s) of drugs wil
150 ended given the lower potency of second-line antituberculosis drugs; and strategies to improve treatm
151 ted a specific function of the sst1 locus in antituberculosis immunity in vivo, especially its role i
153 otentially important implications for global antituberculosis immunization policies and future tuberc
155 -dihydro-imidazooxazole derivative, is a new antituberculosis medication that inhibits mycolic acid s
157 in which (i) specimens from patients taking antituberculosis medications are excluded from testing a
158 at host factors such as poor compliance with antituberculosis medications or decreased absorption of
161 ycobacterium bovis BCG, induced considerable antituberculosis protective immunity in immune-deficient
164 ntrolled trial comparing a standard, 9-month antituberculosis regimen (containing rifampicin 10 mg/kg
166 th tuberculosis treated with a thrice-weekly antituberculosis regimen are at a higher risk of ARR, co
172 ntribution of CD4+ T cells to the protective antituberculosis response involves the production of Th1
175 , the mechanisms of action of the front-line antituberculosis therapeutic agent isoniazid (INH) remai
181 umen is still needed to decide when to start antituberculosis therapy and continued research for bett
182 a promising tool for monitoring response to antituberculosis therapy and evaluating the efficacy of
183 sociation between weight gain or loss during antituberculosis therapy and relapse has not been well s
184 three patients (nine specimens) who were on antituberculosis therapy before the study began were exc
186 plicates combined antiretroviral therapy and antituberculosis therapy in HIV-1-coinfected tuberculosi
187 to identify clinical studies performed with antituberculosis therapy in which PK/PD data and/or para
189 ricidal activity during the initial phase of antituberculosis therapy is due to the depletion of Myco
190 erculosis exposure, previous active disease, antituberculosis therapy status, etc., were considered i
191 uggest the potential for host-based, adjunct antituberculosis therapy targeting lipid metabolism.
193 e 6 months (n = 104) or 9 months (n = 93) of antituberculosis therapy using intermittent directly obs
194 vity in culture-negative children started on antituberculosis therapy was 2% (1-3) for expectorated o
195 s bacteraemia who were not already receiving antituberculosis therapy, 13 (45%) had an abnormal chest
207 sis (TB) patients who move before completing antituberculosis treatment have not been described.
208 tiretroviral therapy (ART) initiation during antituberculosis treatment in co-infected patients.
209 usceptibility testing and suboptimal initial antituberculosis treatment in settings with a high preva
210 n-susceptible tuberculosis were recruited at antituberculosis treatment initiation in Khayelitsha, So
212 icentre randomised clinical trial REMoxTB of antituberculosis treatment on a weekly basis (weeks 0 to
216 arance in patients taking both efavirenz and antituberculosis treatment was highly dependent on NAT2
219 Ocular inflammation reacted favorably to antituberculosis treatment, although only a small minori
220 the end of (6 months) and after (12 months) antituberculosis treatment, and compared to individuals
222 ne were administered in addition to standard antituberculosis treatment, including rifampicin and iso
223 10 tuberculosis patients 10 +/- 2 days post-antituberculosis treatment, there was no detectable STAT
224 CrI: 82; 98) of CPTB-positive cases received antituberculosis treatment, which indicates substantial
229 HIV infection, immunosuppressive therapies, antituberculosis treatments, and other poorly understood
230 ic that is an essential component of current antituberculosis treatments, particularly in the case of
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。